BiotechTube

Ribavirin (Virazole) Injection

Phase 2Withdrawn
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Crimean-Congo Hemorrhagic Fever

Conditions

Crimean-Congo Hemorrhagic Fever, Lassa Fever

Trial Timeline

Sep 1, 2009 → Dec 17, 2019

NCT ID
NCT00992693

About Ribavirin (Virazole) Injection

Ribavirin (Virazole) Injection is a phase 2 stage product being developed by Bausch Health for Crimean-Congo Hemorrhagic Fever. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00992693. Target conditions include Crimean-Congo Hemorrhagic Fever, Lassa Fever.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00992693Phase 2Withdrawn

Other Products from Bausch Health

nabiloneApproved
80
High dose budesonide rectal foam + Low dose budesonide rectal foam + Matching placebo rectal foamApproved
80
benzoyl peroxide wash + Tretinoin gelApproved
80
Adapalene Gel + Tretinoin GelApproved
80
Omeprazole/sodium bicarbonateApproved
80